Vetr upgraded shares of Gilead Sciences (NASDAQ:GILD) from a buy rating to a strong-buy rating in a research report sent to investors on Monday morning. They currently have $91.25 target price on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on the stock. Berenberg Bank set a $96.00 target price on shares of Gilead Sciences and gave the stock a buy rating in a report on Thursday, October 19th. BMO Capital Markets lowered their target price on shares of Gilead Sciences from $89.00 to $83.00 and set an outperform rating on the stock in a report on Friday, October 27th. Credit Suisse Group reissued a buy rating and issued a $82.00 target price on shares of Gilead Sciences in a report on Thursday, December 7th. Maxim Group set a $94.00 target price on shares of Gilead Sciences and gave the stock a buy rating in a report on Monday, December 11th. Finally, Mizuho boosted their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a buy rating in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of Buy and an average target price of $87.04.

Gilead Sciences (NASDAQ:GILD) opened at $81.82 on Monday. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $89.54. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48. The company has a market cap of $106,850.00, a price-to-earnings ratio of 23.51, a PEG ratio of -1.83 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the previous year, the firm earned $2.70 earnings per share. The company’s quarterly revenue was down 18.7% compared to the same quarter last year. research analysts expect that Gilead Sciences will post 6.24 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.79%. Gilead Sciences’s payout ratio is 59.77%.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the transaction, the insider now owns 3,070,099 shares in the company, valued at $230,196,023.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John C. Martin sold 50,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the transaction, the insider now owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold 418,333 shares of company stock worth $32,742,108 in the last quarter. Company insiders own 1.30% of the company’s stock.

A number of hedge funds have recently bought and sold shares of GILD. BlackRock Inc. grew its holdings in shares of Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the last quarter. FMR LLC grew its holdings in shares of Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the last quarter. Finally, Parnassus Investments CA grew its holdings in shares of Gilead Sciences by 2.5% in the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock worth $1,372,604,000 after purchasing an additional 464,609 shares during the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/15/gilead-sciences-gild-upgraded-to-strong-buy-by-vetr.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.